肿瘤防治研究2024,Vol.51Issue(12) :994-999.DOI:10.3971/j.issn.1000-8578.2024.24.0824

食管癌新辅助免疫治疗联合化疗的研究进展和热点问题

Recent Advances and Hot Spots of Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Carcinoma

吕会来 盖春月 王明博 李振华 李嘉宸 许石 丁伟禄 刘宇 田子强
肿瘤防治研究2024,Vol.51Issue(12) :994-999.DOI:10.3971/j.issn.1000-8578.2024.24.0824

食管癌新辅助免疫治疗联合化疗的研究进展和热点问题

Recent Advances and Hot Spots of Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Carcinoma

吕会来 1盖春月 1王明博 1李振华 1李嘉宸 1许石 1丁伟禄 1刘宇 1田子强1
扫码查看

作者信息

  • 1. 050011 石家庄,河北医科大学第四医院胸外科,河北省食管癌精准诊断与综合治疗重点实验室
  • 折叠

摘要

以手术为基础的综合治疗是局部晚期食管癌的首选治疗策略,目前指南推荐的新辅助治疗方案包括新辅助化疗和新辅助放化疗.随着免疫时代到来,新辅助免疫治疗联合化疗备受关注,首个Ⅲ期研究也证实新辅助免疫联合化疗是一种有前景的治疗选择.本文将对目前新辅助免疫治疗联合化疗的研究进展和热点问题进行梳理和简要综述.

Abstract

Surgery-based multidisciplinary comprehensive treatment is the preferred treatment strategy for local advanced esophageal cancer.Neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy have been recommended by the Chinese Society of Clinical Oncology(CSCO)guideline.With the advent of imm-unotherapy,neoadjuvant immunotherapy combined with chemotherapy has received much attention,and the first phase Ⅲ study has also confirmed that neoadjuvant immunotherapy combined chemotherapy is a promising treatment option.This article will review the recent advances and hot spots of neoadjuvant immunotherapy combined with chemotherapy.

关键词

食管癌/新辅助治疗/免疫治疗联合化疗

Key words

Esophageal cancer/Neoadjuvant treatment/Immunotherapy combined with chemotherapy

引用本文复制引用

出版年

2024
肿瘤防治研究
湖北省卫生厅,中国抗癌协会,湖北省肿瘤医院

肿瘤防治研究

CSTPCD
影响因子:0.737
ISSN:1000-8578
段落导航相关论文